一款鼻炎药成爆款,康诺亚收入暴涨812%,但这样的“增长神话”还有点虚

钛媒体APP
Sep 23, 2025

文 | 医药研究社康诺亚的爆款效应越来越明显了。今年上半年,康诺亚自主研发的1类新药司普奇拜单抗(CM310)(商品名:康悦达)销售额达1.69亿元,直接推动了业绩爆发式增长,同期公司总收入达到4.99亿元,同比增长812%,亏损也同比大幅收窄了77%。具体来看,司普奇拜单抗这款药上市时间并不算很长,2024年9月获批用于治疗成人中重度特应性皮炎,2024年12月获批用于治疗慢性鼻窦炎伴鼻息肉,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10